Published in J Immunol on January 01, 1990
TOR controls translation initiation and early G1 progression in yeast. Mol Biol Cell (1996) 8.03
Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J (1996) 6.08
Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A (1990) 3.70
Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A (1992) 2.98
The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem (2007) 2.77
Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands. EMBO J (1994) 2.06
Rapamycin sensitivity in Saccharomyces cerevisiae is mediated by a peptidyl-prolyl cis-trans isomerase related to human FK506-binding protein. Mol Cell Biol (1991) 2.03
The Pim kinases control rapamycin-resistant T cell survival and activation. J Exp Med (2005) 1.99
Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplant (2008) 1.96
Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. Proc Natl Acad Sci U S A (1992) 1.82
Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc Natl Acad Sci U S A (1994) 1.76
BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription. Blood (2011) 1.61
Lymphocyte activation induces rapid changes in nuclear and cytoplasmic glycoproteins. Proc Natl Acad Sci U S A (1991) 1.60
Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13. Proc Natl Acad Sci U S A (1991) 1.58
Regulatory pathways governing modulation of fungal gene expression by a virulence-attenuating mycovirus. EMBO J (1992) 1.52
Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Exp Med (1991) 1.48
Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology (1991) 1.48
Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci U S A (1994) 1.41
Tumor necrosis factor alpha is an autocrine growth factor for normal human B cells. Proc Natl Acad Sci U S A (1994) 1.28
The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med (1992) 1.27
Mechanisms of T-cell activation by human T-cell lymphotropic virus type I. Microbiol Mol Biol Rev (1999) 1.27
Rapamycin specifically interferes with the developmental response of fission yeast to starvation. J Bacteriol (1997) 1.25
Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. Mol Cell Biol (1991) 1.22
Calcineurin mediates human tumor necrosis factor alpha gene induction in stimulated T and B cells. J Exp Med (1994) 1.22
The immunosuppressant FK506 inhibits amino acid import in Saccharomyces cerevisiae. Mol Cell Biol (1993) 1.19
A novel FK506- and rapamycin-binding protein (FPR3 gene product) in the yeast Saccharomyces cerevisiae is a proline rotamase localized to the nucleolus. J Cell Biol (1994) 1.19
The immunosuppressant rapamycin represses human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (2002) 1.16
Signaling through the interleukin 2 receptor beta chain activates a STAT-5-like DNA-binding activity. Proc Natl Acad Sci U S A (1995) 1.16
Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol (1992) 1.14
Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription. Proc Natl Acad Sci U S A (1991) 1.10
FK506 inhibits antigen receptor-mediated induction of c-rel in B and T lymphoid cells. J Exp Med (1995) 1.07
Effects of rapamycin on cultured hepatocyte proliferation and gene expression. Hepatology (1992) 1.06
Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol (2007) 1.02
Rapamycin destabilizes interleukin-3 mRNA in autocrine tumor cells by a mechanism requiring an intact 3' untranslated region. Mol Cell Biol (1997) 1.01
Inhibition of liver, kidney, and intestine regeneration by rapamycin. Transplantation (1992) 1.00
Statin prevents chondrocyte aging and degeneration of articular cartilage in osteoarthritis (OA). Aging (Albany NY) (2010) 0.98
Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. Transplant Proc (1991) 0.95
Hypersensitivity to rapamycin of BJAB B lymphoblastoid cells. Immunology (1996) 0.92
Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo. Mediators Inflamm (1999) 0.92
Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J Clin Invest (1997) 0.91
A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica (2014) 0.91
Comparison of the effects of FK-506, cyclosporin A and rapamycin on IL-2 production. Immunology (1991) 0.91
A kinase-dead knock-in mutation in mTOR leads to early embryonic lethality and is dispensable for the immune system in heterozygous mice. BMC Immunol (2009) 0.89
Insight into the role of mTOR and metabolism in T cells reveals new potential approaches to preventing graft rejection. Curr Opin Organ Transplant (2014) 0.89
Effects of cyclosporin A and a rapamycin derivative (SAR943) on chronic allergic inflammation in sensitized rats. Immunology (2003) 0.89
Rapamycin decreases leukocyte migration in vivo and effectively reduces experimentally induced chronic colitis. Int J Colorectal Dis (2005) 0.88
The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. Mol Cell Biol (1991) 0.88
The role and regulation of mTOR in T-lymphocyte function. Arch Immunol Ther Exp (Warsz) (2012) 0.88
Structure comparison of native and mutant human recombinant FKBP12 complexes with the immunosuppressant drug FK506 (tacrolimus). Protein Sci (1995) 0.87
Rapamycin attenuates airway hyperreactivity, goblet cells, and IgE in experimental allergic asthma. J Immunol (2011) 0.87
The spectrum of action of new immunosuppressive drugs. Clin Exp Immunol (1992) 0.87
T cell selective apoptosis by a novel immunosuppressant, FTY720, is closely regulated with Bcl-2. Br J Pharmacol (2002) 0.86
Cyclophilin-dependent stimulation of transcription by cyclosporin A. Proc Natl Acad Sci U S A (1993) 0.85
Therapeutic effect of a new immunosuppressive agent, everolimus, on interleukin-10 gene-deficient mice with colitis. Clin Exp Immunol (2007) 0.83
Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients. Br J Clin Pharmacol (2009) 0.83
Inhibition of CD25 (IL-2R alpha) expression and T-cell proliferation by polyclonal anti-thymocyte globulins. Immunology (1992) 0.82
A human class II MHC-derived peptide antagonizes phosphatidylinositol 3-kinase to block IL-2 signaling. J Clin Invest (2000) 0.82
FK-506-binding proteins from streptomycetes producing immunosuppressive macrolactones of the FK-506 type. J Bacteriol (1992) 0.81
Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. Transplantation (1994) 0.81
Effects of cyclosporine and rapamycin on immunoglobulin production by preactivated human B cells. Clin Exp Immunol (1994) 0.81
The effect of cyclosporin A, FK506 and rapamycin on the murine contact sensitivity reaction. Clin Exp Immunol (1998) 0.81
Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island. J Gerontol A Biol Sci Med Sci (2016) 0.80
Global analysis of serine/threonine and tyrosine protein phosphatase catalytic subunit genes in Neurospora crassa reveals interplay between phosphatases and the p38 mitogen-activated protein kinase. G3 (Bethesda) (2014) 0.80
What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J Gastroenterol (2014) 0.79
Rapamycin rescues the poor developmental capacity of aged porcine oocytes. Asian-Australas J Anim Sci (2014) 0.79
Comparison of the properties of the CsA analogs monoacetyl CyC (o-acetyl-threonine2 cyclosporin) and methyl-alanyl CsA (N-methyl-L-alanyl6 cyclosporin); monoacetyl cyclosporin is immunosuppressive without binding to cyclophilin. Clin Exp Immunol (1992) 0.78
Effects on in vivo and in vitro hepatocyte proliferation of methylprednisolone, azathioprine, mycophenolic acid, mizoribine, and prostaglandin E1. Transplant Proc (1992) 0.78
Treating metastatic soft-tissue or bone sarcomas - potential role of ridaforolimus. Onco Targets Ther (2012) 0.77
Anti-CD28 antibody- and IL-4-induced human T cell proliferation is sensitive to rapamycin. Clin Exp Immunol (1993) 0.77
The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response--an in vivo model of Th2-like activity. Clin Exp Immunol (1995) 0.77
Suppressive activity of a macrolide antibiotic, roxithromycin on co-stimulatory molecule expression on mouse splenocytes in vivo. Mediators Inflamm (2000) 0.77
Modulation of T cell proliferation and cytokine response by Plumbagin, extracted from Plumbago zeylanica in collagen induced arthritis. BMC Complement Altern Med (2011) 0.77
A new functional role for mechanistic/mammalian target of rapamycin complex 1 (mTORC1) in the circadian regulation of L-type voltage-gated calcium channels in avian cone photoreceptors. PLoS One (2013) 0.77
Effects of immunomodulators on airways hyperresponsiveness to adenosine induced in actively sensitised Brown Norway rats by exposure to allergen. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.76
Expression, localisation and functional activation of NFAT-2 in normal human skin, psoriasis, and cultured keratocytes. Int J Clin Exp Med (2009) 0.76
Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia. J Hematol Oncol (2016) 0.75
Should diabetic women with breast cancer have their own intervention studies? Endocr Relat Cancer (2012) 0.75
Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. Transplant Proc (1991) 0.75
The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. Transplant Proc (1991) 0.75
David and Goliath: chemical perturbation of eukaryotes by bacteria. J Ind Microbiol Biotechnol (2015) 0.75
mTOR function and therapeutic targeting in breast cancer. Am J Cancer Res (2017) 0.75
Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts. Eur J Clin Pharmacol (2011) 0.75
Ubiquitin-like Atg8 protein is expressed during autophagy and the encystation process in Naegleria gruberi. Parasitol Res (2016) 0.75
A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature (1989) 5.53
Assessing B cell diversification by antigen receptor and precursor cell analysis. Ann Immunol (Paris) (1976) 3.88
The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol (1990) 2.11
The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. Am J Cardiol (1997) 1.98
Production of antibodies of identical idiotype but diverse immunoglobulin classes by cells derived from a single stimulated B cell. Proc Natl Acad Sci U S A (1975) 1.96
Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immunol (1997) 1.80
The four biochemically distinct species of human interleukin 1 all exhibit similar biologic activities. J Immunol (1985) 1.78
Heterogeneity of the BALB/c antiphosphorylcholine antibody response at the precursor cell level. J Exp Med (1975) 1.75
Voltage-gated potassium channels regulate calcium-dependent pathways involved in human T lymphocyte activation. J Exp Med (1993) 1.67
CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells. J Virol (2001) 1.66
Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group. Am J Cardiol (1998) 1.56
The frequency of phosphorylcholine-specific B cells in conventional and germfree BALB/C mice. J Immunol (1975) 1.55
Human cytotoxic lymphocyte granzyme B. Its purification from granules and the characterization of substrate and inhibitor specificity. J Biol Chem (1991) 1.51
FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. Proc Natl Acad Sci U S A (1991) 1.49
Differential expression of an equivalent clonotype among BALB/c and C57BL/6 mice. J Exp Med (1978) 1.49
Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J Exp Med (1991) 1.48
Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol (1990) 1.37
The adjuvanticity of interleukin 1 in vivo. J Immunol (1983) 1.35
Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J Immunol (1998) 1.32
Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem (1998) 1.32
The cytosolic-binding protein for the immunosuppressant FK-506 is both a ubiquitous and highly conserved peptidyl-prolyl cis-trans isomerase. J Biol Chem (1990) 1.30
Immunochemical evidence in two haplotypes for at least three D region-encoded molecules, D, L, and R. J Immunol (1981) 1.29
Lipid-altering efficacy and safety of simvastatin 80 mg/day: long-term experience in a large group of patients with hypercholesterolemia. World Wide Expanded Dose Simvastatin Study Group. Clin Cardiol (2000) 1.27
The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. J Exp Med (1992) 1.27
Expression of phosphorylcholine-specific B cells during murine development. J Exp Med (1977) 1.19
Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol (1999) 1.19
FK-506, a potent novel immunosuppressive agent, binds to a cytosolic protein which is distinct from the cyclosporin A-binding protein, cyclophilin. J Immunol (1989) 1.18
Regulation of azophenylarsonate-specific repertoire expression. 1. Frequency of cross-reactive idiotype-positive B cells in A/J and BALB/c mice. J Exp Med (1982) 1.17
The B-cell clonotype repertoire. Adv Immunol (1978) 1.16
The monoclonal anti-phosphorylcholine antibody response in several murine strains: genetic implications of a diverse repertoire. J Exp Med (1977) 1.15
FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol (1991) 1.12
Heterogeneity of EBV-transformable human B lymphocyte populations. J Immunol (1986) 1.09
Reduction of serum Interleukin-1-like activity after treatment with dexamethasone. J Leukoc Biol (1985) 1.09
Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc Natl Acad Sci U S A (2000) 1.08
Late acquisition of a germ line antibody specificity. Nature (1976) 1.05
New technologies for high-throughput screening. Curr Opin Chem Biol (1997) 1.02
A study of the correlation between cyclophilin binding and in vitro immunosuppressive activity of cyclosporine A and analogues. Transplant Proc (1988) 0.98
Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. Cell Immunol (1995) 0.98
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis (1997) 0.97
Human monoclonal antibodies that protect mice against challenge with Pseudomonas aeruginosa. Infect Immun (1988) 0.95
Relationship between multiple biologic effects of rapamycin and the inhibition of pp70S6 protein kinase activity. Analysis in mutant clones of a T cell lymphoma. J Immunol (1994) 0.95
Human cytotoxic lymphocyte tryptase. Its purification from granules and the characterization of inhibitor and substrate specificity. J Biol Chem (1988) 0.94
FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. Curr Opin Immunol (1992) 0.94
X-linked immunodeficient mice as a model for testing the protective efficacy of monoclonal antibodies against Pseudomonas aeruginosa. Infect Immun (1988) 0.93
Genetic influences on the adjuvanticity of muramyl dipeptide in vivo. J Immunol (1982) 0.93
Large, activated B cells are the primary B-cell target of 8-bromoguanosine and 8-mercaptoguanosine. Cell Immunol (1987) 0.92
The interplay of evolution and environment in B-cell diversification. Cold Spring Harb Symp Quant Biol (1977) 0.92
Idiotype-specific neonatal suppression of phosphorylcholine-responsive B cells. Eur J Immunol (1977) 0.92
Novel idiotypic and antigen-binding characteristics in two anti-dinitrophenyl monoclonal antibodies. J Exp Med (1977) 0.90
Heterogeneity of the BALB/c IgM anti-phosphorylcholine antibody response. Nature (1982) 0.90
FK-506--a novel immunosuppressant. Ann N Y Acad Sci (1993) 0.89
Expression of a bone marrow-associated Ly-6 determinant on the T cell population expanding in the lymph nodes of the autoimmune mouse strain MRL/Mp-lpr/lpr. J Immunol (1983) 0.89
Isolation of a human cDNA encoding a 25 kDa FK-506 and rapamycin binding protein. Biochem Biophys Res Commun (1992) 0.88
Limiting dilution analysis of Epstein-Barr virus-induced immunoglobulin production. Cell Immunol (1983) 0.88
Patterns of isotype commitment in human B cells: limiting dilution analysis of Epstein Barr virus-infected cells. J Immunol (1983) 0.87
Heterogeneity of the human phosphocholine-specific B cell repertoire. J Immunol (1984) 0.87
Regulation of class II MHC molecules on human endothelial cells. Effects of IFN and dexamethasone. J Immunol (1988) 0.86
The frequency of para-azophenylarsonate and dimethylaminonapthalene-sulfonyl-specific B cells in neonatal and adult BALB/c mice. J Immunol (1977) 0.86
IL-2 induces expression of serine protease enzymes and genes in natural killer and nonspecific T killer cells. J Immunol (1989) 0.86
In vitro regulation of IgA subclass production. III. Selective transformation of IgA1 producing cells by Epstein-Barr virus. J Immunol (1987) 0.86
In vitro tolerance induction of neonatal murine B cells as a probe for the study of B-cell diversification. J Exp Med (1977) 0.85
The human and murine influenza-specific B cell repertoires share a common idiotope. J Immunol (1987) 0.84
Modulation of chronic lymphocytic leukemia cells by phorbol ester: increase in Ia expression, IgM secretion and MLR stimulatory capacity. J Immunol (1982) 0.84
Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. Int J Immunopharmacol (1991) 0.83
Idiotypic and fluorometric analysis of the antibodies that distinguish the lesion of the I-A mutant B6.C-H-2bm12. J Immunol (1983) 0.83
FK-506 and cyclosporin A: selective inhibition of calcium ionophore-induced polymorphonuclear leukocyte degranulation. Biochem Pharmacol (1991) 0.83
Lipid-altering efficacy and safety of simvastatin 80 mg/day: worldwide long-term experience in patients with hypercholesterolemia. Nutr Metab Cardiovasc Dis (2000) 0.82
Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol (1993) 0.82
A human monoclonal antibody that protects mice against Pseudomonas-induced pneumonia. J Infect Dis (1990) 0.82
Unexpected up-regulation of gene expression by cyclosporin A and FK-506 in a T-cell lymphoma: both immunosuppressants augment Ly-6E antigen induction by interferon-gamma in the presence of ionomycin. Int J Immunopharmacol (1991) 0.82
The enzymatic activity of human cytotoxic T-lymphocyte granzyme A and cytolysis mediated by cytotoxic T-lymphocytes are potently inhibited by a synthetic antiprotease, FUT-175. Arch Biochem Biophys (1991) 0.81
Hypothemycin inhibits the proliferative response and modulates the production of cytokines during T cell activation. Immunopharmacology (1999) 0.81
Activation of murine natural killer cells and macrophages by 8-bromoguanosine. J Immunol (1988) 0.81
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin (2001) 0.81
Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels. Am J Cardiol (2000) 0.81
Characterization of H-2Db antigens implies haplotype differences in the number of H-2 molecules expressed. J Immunol (1982) 0.80
A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. Transplantation (1998) 0.80
5-Halo-6-phenyl pyrimidinones and 8-substituted guanosines: biological response modifiers with similar effects on B cells. Cell Immunol (1988) 0.79
Recent advances in the mechanism of action of cyclosporine and FK506. Curr Opin Nephrol Hypertens (1992) 0.79
Control of the mitogenicity of muramyl dipeptide. Int J Immunopharmacol (1981) 0.79
A paradigm for drug discovery employing encoded combinatorial libraries. Proc Natl Acad Sci U S A (1995) 0.79
Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. Transplant Proc (1991) 0.78
FKBP, the binding protein for the immunosuppressive drug, FK-506, is not an inhibitor of protein kinase C activity. Biochem Biophys Res Commun (1991) 0.78
Long-term passive enhancement of allogeneic skin grafts with monoclonal antibodies. J Immunogenet (1985) 0.77
Mixed agonist/antagonist activity of an FK-506-related immunosuppressant: biological and biochemical characterization. J Pharmacol Exp Ther (1996) 0.77
Up-regulation of gene expression by FK 506. Transplant Proc (1991) 0.77
An ELISA assay for murine amyloid A and serum amyloid A utilizing monoclonal antibodies. J Immunol Methods (1982) 0.77
Small molecule antagonists of the bradykinin B1 receptor. Immunopharmacology (1999) 0.76
Functional consequences of perceived interleukin deficiencies? Analysis employing NZB x C58 recombinant inbred mice. Clin Exp Immunol (1985) 0.75